Products and processes

Claim 2

A technetium [99m](I) complex selected from the group of complexes having the following formulae: 99m Tc(I)[P(R 1 ,R 2 ,R 3 )] 6 + A - 1 wherein R 1 , R 2 and R 3 are independently selected from the group consisting of lower alkyl, lower alkoxy, and lower alkoxy lower alkyl provided each phosphorous is bonded through at least one oxygen to a carbon; and A - is a non-deleterious, chemically suitable, pharmaceutically acceptable anion; .sup.99m Tc(I)[P(X,R.sup.1)].sub.6.sup.+ A.sup.- 2 wherein X is a bridging substituent selected from the group consisting of lower alkylenedioxy, and lower oxyalkyl; R 1 has the same meaning as set forth above, provided each phosphorous is bonded through at least one oxygen to a carbon, and A - has the same meaning as set forth above; .sup.99m Tc(I)[PY].sub.6.sup.+ A.sup.- 3 wherein Y is a trivalent bridging substituent selected from the group consisting of lower tri(oxyalkylene)alkane, lower oxydialkyl, and lower dioxyalkyl, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; .sup.99m Tc(I)[R.sup.4,R.sup.5 --P--R.sup.6 --P--R.sup.7, R.sup.8 ].sub.3.sup.+ A.sup.- 4 wherein R 4 , R 5 , R 7 and R 8 are independently selected from the group consisting of, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R 6 is a linking substituent selected from the group consisting of lower alkylene, oxygen, lower alkylenedioxy and lower oxyalkylene, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; and .sup.99m Tc(I)[X--P--R.sup.6 --P--X].sub.3.sup.+ A.sup.- 5 wherein X, R 6 and A - have the same meaning as set forth above and provided each phosphorous is bonded through at least one oxygen to a carbon.

Claim 3

A complex according to claim 1 selected from the group of complexes represented by formula 1 of claim 1.

Claim 4

A complex according to claim 2, wherein the anion is selected from the group consisting of Cl - , H 2 PO 4 - , HPO 4 -2 and PO 4 -3 .

Claim 5

A complex according to claim 3 wherein R 1 and R 2 are methoxy and R 3 is methyl.

Claim 6

A complex according to claim 3 wherein R 1 and R 2 are methyl and R 3 is methoxy.

Claim 7

A complex according to claim 3 wherein R 1 , R 2 and R 3 are ethoxy.

Claim 8

A complex according to claim 3 wherein R 1 , R 2 and R 3 are methoxy.

Claim 9

A complex according to claim 1 selected from the group of complexes represented by formula 2 of claim 1.

Claim 10

A complex according to claim 1 selected from the group of complexes represented by formula 3 of claim 1.

Claim 11

A complex according to claim 1 selected from the group of complexes represented by formula 4 of claim 1.

Claim 12

A complex according to claim 1 selected from the group of complexes represented by formula 5 of claim 1.

Claim 13

An imaging composition containing a technetium [99m](I) complex selected from the group of complexes having the following formulae: .sup.99m Tc(I)[P(R.sup.1,R.sup.2,R.sup.3)].sub.6.sup.+ A.sup.- 1 wherein R 1 , R 2 and R 3 are independently selected from the group consisting of lower alkyl, lower alkoxy, and lower alkoxy lower alkyl provided each phosphorous is bonded through at least one oxygen to a carbon; and A - is a non-deleterious, chemically suitable, pharmaceutically acceptable anion; .sup.99m Tc(I)[P(X,R.sup.1)].sub.6.sup.+ A.sup.- 2 wherein X is a bridging substituent selected from the group consisting of lower alkylenedioxy, and lower oxyalkyl; R 1 has the same meaning as set forth above, provided each phosphorous is bonded through at least one oxygen to a carbon, and A - has the same meaning as set forth above; .sup.99m Tc(I)[PY].sub.6.sup.+ A.sup.- 3 wherein Y is a trivalent bridging substituent selected from the group consisting of lower tri(oxyalkylene)alkane, lower oxydialkyl, and lower dioxyalkyl, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; .sup.99m Tc(I)[R.sup.4,R.sup.5 --P--R.sup.6 --P--R.sup.7,R.sup.8 ].sub.3.sup.+ A.sup.- 4 wherein R 4 , R 5 , R 7 and R 8 are independently selected from the group consisting of, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R 6 is a linking substituent selected from the group consisting of lower aklylene, oxygen, lower alkylenedioxy and lower oxyalkylene, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; and .sup.99m Tc(I)[X--P--R.sup.6 --P--X].sub.3.sup.+ A.sup.- 5 wherein X, R 6 and A - have the same meaning as set forth above and provided each phosphorous is bonded through at least one oxygen to a carbon in a sufficient amount to provide satisfactory imaging together with a pharmaceutically acceptable vehicle.

Claim 14

An imaging composition containing a technetium [99m](I) complex selected from the group of complexes having the following formulae: .sup.99m Tc(I)[P(R.sup.1,R.sup.2,R.sup.3)].sub.6.sup.+ A.sup.- 1 wherein R 1 , R 2 and R 3 are independently selected from the group consisting of lower alkyl, lower alkoxy, and lower alkoxy lower alkyl provided each phosphorous is bonded through at least one oxygen to a carbon; and A - is a non-deleterious, chemically suitable, pharmaceutically acceptable anion; .sup.99m Tc(I)[P(X,R.sup.1)].sub.6.sup.+ A.sup.- 2 wherein X is a bridging substituent selected from the group consisting of lower alkylenedioxy, and lower oxyalkyl; R 1 has the same meaning as set forth above, provided each phosphorous is bonded through at least one oxygen to a carbon, and A - has the same meaning as set forth above; .sup.99m Tc(I)[PY].sub.6.sup.+ A.sup.- 3 wherein Y is a trivalent bridging substituent selected from the group consisting of lower tri(oxyalkylene)alkane, lower oxydialkyl, and lower dioxyalkyl, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; .sup.99m Tc(I)[R.sup.4,R.sup.5 --P--R.sup.6 --P--R.sup.7,R.sup.8 ].sub.3.sup.+ A.sup.- 4 wherein R 4 , R 5 , R 7 and R 8 are independently selected from the group consisting of, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R 6 is a linking substituent selected from the group consisting of lower aklylene, oxygen, lower alkylenedioxy and lower oxyalkylene, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; and .sup.99m Tc(I)[X--P--R.sup.6 --P--X].sub.3.sup.+ A.sup.- 5 wherein X, R 6 and A - have the same meaning as set forth above and provided each phosphorous is bonded through at least one oxygen to a carbon in a sufficient amount to provide satisfactory imaging together with a pharmaceutically acceptable vehicle.

Claim 15

A composition according to claim 12 wherein said complex is selected from the group of complexes represented by formula 1 of claim 12.

Claim 16

A composition according to claim 13, wherein the anion is selected from the group consisting of Cl - , H 2 PO 4 - , HPO 4 -2 and PO 4 3 .

Claim 17

A composition according to claim 14 wherein R 1 and R 2 are methoxy and R 3 is methyl.

Claim 18

A composition according to claim 14 wherein R 1 and R 2 are methyl and R 3 is methoxy.

Claim 19

A composition according to claim 14 wherein R 1 , R 2 and R 3 are ethoxy.

Claim 20

A composition according to claim 14 wherein R 1 , R 2 and R 3 are methoxy.

Claim 21

A composition according to claim 12 selected from the group of complexes having formula 2 of claim 12.

Claim 22

A composition according to claim 12 selected from the group of complexes represented by formula 3 of claim 12.

Claim 23

A composition according to claim 12 selected from the group of complexes represented by formula 4 of claim 12.

Claim 24

A composition according to claim 12 selected from the group of complexes represented by formula 5 of claim 12.

Claim 25

In a method for imaging wherein a composition containing a technetium [99m](I) complex in a pharmaceutically acceptable vehicle is injected into a living animal body in a sufficient amount to provide adequate imaging and thereafter imaging carried out, the improvement comprising utilizing as the composition a composition containing a technetium [99m](I) complex selected from the group of complexes having the following formulae: .sup.99m Tc(I)[P(R.sup.1,R.sup.2,R.sup.3)].sub.6.sup.+ A.sup.- 1 wherein R 1 , R 2 and R 3 are independently selected from the group consisting of lower alkyl, lower alkoxy, and lower alkoxy lower alkyl provided each phosphorous is bonded through at least one oxygen to a carbon; and A - is a non-deleterious, chemically suitable, pharmaceutically acceptable anion; .sup.99m Tc(I)[P(X,R.sup.1)].sub.6.sup.+ A.sup.- 2 wherein X is a bridging substituent selected from the group consisting of lower alkylenedioxy, and lower oxyalkyl; R 1 has the same meaning as set forth above, provided each phosphorous is bonded through at least one oxygen to a carbon, and A - has the same meaning a set forth above; .sup.b 99m Tc(I)[PY].sub.6.sup.+ A.sup.- 3 wherein Y is a trivalent bridging substituent selected from the group consisting of lower tri(oxyalkylene)alkane, lower oxydialkyl, and lower dioxyalkyl, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; .sup.99m Tc(I)[R.sup.4,R.sup.5 --P--R.sup.6 --P--R.sup.7,R.sup.8 ].sub.3.sup.+ A.sup.- 4 wherein R 4 ,R 5 ,R 7 and R 8 are independently selected from the group consisting of, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R 6 is a linking substituent selected from the group consisting of lower alkylene, oxygen, lower alkylenedioxy and lower oxyalkylene, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; and .sup.99m Tc(I)[X--P--R.sup.6 --P--X].sub.3.sup.+ A.sup.- 5 wherein X, R 6 and A - have the same meaning as set forth above and provided each phosphorous is bonded through at least one oxygen to a carbon in a sufficient amount to provide satisfactory myocardial imaging together with a pharmaceutically acceptable vehicle.

Claim 26

In a method for imaging wherein a composition containing a technetium [99m](I) complex in a pharmaceutically acceptable vehicle is injected into a living animal body in a sufficient amount to provide adequate imaging and thereafter imaging carried out, the improvement comprising utilizing as the composition a composition containing a technetium [99m](I) complex selected from the group of complexes having the following formulae: .sup.99m Tc(I)[P(R.sup.1,R.sup.2,R.sup.3)].sub.6.sup.+ A.sup.- 1 wherein R 1 , R 2 and R 3 are independently selected from the group consisting of lower alkyl, lower alkoxy, and lower alkoxy lower alkyl provided each phosphorous is bonded through at least one oxygen to a carbon; and A - is a non-deleterious, chemically suitable, pharmaceutically acceptable anion; .sup.99m Tc(I)[P(X,R.sup.1)].sub.6.sup.+ A.sup.- 2 wherein X is a bridging substituent selected from the group consisting of lower alkylenedioxy, and lower oxyalkyl; R 1 has the same meaning as set forth above, provided each phosphorous is bonded through at least one oxygen to a carbon, and A - has the same meaning a set forth above; .sup.b 99m Tc(I)[PY].sub.6.sup.+ A.sup.- 3 wherein Y is a trivalent bridging substituent selected from the group consisting of lower tri(oxyalkylene)alkane, lower oxydialkyl, and lower dioxyalkyl, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; .sup.99m Tc(I)[R.sup.4,R.sup.5 --P--R.sup.6 --P--R.sup.7,R.sup.8 ].sub.3.sup.+ A.sup.- 4 wherein R 4 ,R 5 ,R 7 and R 8 are independently selected from the group consisting of, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R 6 is a linking substituent selected from the group consisting of lower alkylene, oxygen, lower alkylenedioxy and lower oxyalkylene, provided each phosphorous is bonded through at least one oxygen to a carbon; and A - has the same meaning as set forth above; and .sup.99m Tc(I)[X--P--R.sup.6 --P--X].sub.3.sup.+ A.sup.- 5 wherein X, R 6 and A - have the same meaning as set forth above and provided each phosphorous is bonded through at least one oxygen to a carbon in a sufficient amount to provide satisfactory myocardial imaging together with a pharmaceutically acceptable vehicle.

Claim 27

A method according to claim 23 wherein said complex is selected from the group of complexes represented by formula 1 of claim 23.

Claim 28

A method according to claim 24 wherein the anion is selected from the group consisting of Cl - , H 2 PO 4 - , HPO 4 -2 and PO 4 -3 .

Claim 29

A method according to claim 25 wherein R 1 and R 2 are methoxy and R 3 is methyl.

Claim 30

A method according to claim 25 wherein R 1 and R 2 are methyl and R 3 is methoxy.

Claim 31

A method according to claim 25 wherein R 1 , R 2 and R 3 are ethoxy.

Claim 32

A method according to claim 25 wherein R 1 , R 2 and R 3 are methoxy.

Claim 33

A method according to claim 23 selected from the group of complexes represented by formula 2 of claim 23.

Claim 34

A method according to claim 23 selected from the group of complexes represented by formula 3 of claim 23.

Claim 35

A method according to claim 23 selected from the group of complexes represented by formula 4 of claim 23.

Claim 36

A method according to claim 23 selected from the group of complexes represented by formula 5 of claim 23.